Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) have been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $6.2333.
A number of equities research analysts have recently weighed in on IRWD shares. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a “hold (c-)” rating to a “hold (c+)” rating in a report on Friday. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday.
View Our Latest Research Report on IRWD
Ironwood Pharmaceuticals Price Performance
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The firm had revenue of $113.04 million during the quarter, compared to analysts’ expectations of $114.84 million. As a group, sell-side analysts anticipate that Ironwood Pharmaceuticals will post 1.04 EPS for the current year.
Insider Activity
In other Ironwood Pharmaceuticals news, Director Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director directly owned 250,749 shares of the company’s stock, valued at $935,293.77. The trade was a 7.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ronald Silver sold 127,890 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the sale, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. The trade was a 28.96% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 9.30% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in IRWD. AQR Capital Management LLC boosted its position in Ironwood Pharmaceuticals by 535.8% during the 1st quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company’s stock valued at $3,710,000 after buying an additional 2,126,889 shares during the period. Millennium Management LLC increased its position in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after acquiring an additional 4,140,439 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at about $57,000. Goldman Sachs Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 72.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company’s stock valued at $2,316,000 after acquiring an additional 660,144 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock valued at $5,160,000 after acquiring an additional 3,092,475 shares during the last quarter.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
